Examples of Biogen International in a sentence
The net book value of this asset as of March 31, 2017 was $2,418.6 million.In January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma A/S (Forward Pharma) and certain related parties, which was effective as of February 1, 2017.
BiogenOn December 18, 2019, the Company and Biogen International GmbH (“Biogen”) entered into a License and Collaboration Agreement (the “Biogen Agreement”), under which the Company granted Biogen a worldwide, royalty-bearing, exclusive, with the right to sublicense, license (“Exclusive License”) to develop and commercialize CB 2782-PEG and other anti-C3 proteases for potential treatment of dry age-related macular degeneration (“AMD”) and other disorders.
Biogen International, the Institution and the Physician entered into the Non Interventional Study Agreement signed on 4 May 2009 (the “Agreement”), WHEREAS Biogen assumed the responsibilities of the Study from Biogen International; WHEREAS the Sponsor wishes to take over the rights and obligations of the outgoing Sponsor, who was party to the Agreement, and the outgoing Sponsor wishes to assign all of its rights and obligations under the Agreement and the Study Protocol to the Sponsor.
By: /s/ Xxxxxxxxx Xxxxxx By: /s/ Xxxxxxx Xxxxxxxxx Name: Xx. Xxxxx Xxxxxx Name: Xxxxxx Xxxxxxxxx Title: President and CEO Title: CEO Biogen International GmbH By: /s/ Xxxxxxx Xxxxxx-Xxxxxxx Name: Xxxxxxx Xxxxxx-Xxxxxxx Title: President Europe and Canada [*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
Interim Condensed Financial Statements (Unaudited) For the Three Months EndedMarch 31, 2017 2016 in CHF thousandsCollaboration and license revenue1,955381Grant revenue51106Total revenues2,006487 3.1. Licensing and collaboration agreements 3.1.1 Research Collaboration and license revenue Alpha-synuclein and TDP-43 PET Imaging Tracers - Collaboration with Biogen On April 13, 2016, AC Immune entered into a non-exclusive research collaboration agreement with Biogen International GmbH, or Biogen.
The net book values of the TYSABRI and TECFIDERA assets as of June 30, 2018, were $2,120.8 million and $291.4 million, respectively.TECFIDERA License RightsIn January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017.
Member further understands that Biogen International GmbH strongly recommends, particularly for those members who are not currently on a regular exercise program, to consult with a physician prior to beginning any course of exercise.
Biogen International GmbH is a corporation orga- nized under the laws of Switzerland with its principal place of business at Landis + Gyr-Strasse 3, 6300 Zug, Switzerland.
The net book values of the TYSABRI and TECFIDERA assets as of September 30, 2018, were $2,073.6 million and $262.6 million, respectively.TECFIDERA License RightsIn January 2017 we entered into a settlement and license agreement among Biogen Swiss Manufacturing GmbH, Biogen International Holding Ltd., Forward Pharma and certain related parties, which was effective as of February 1, 2017.
The patent holder (Biogen International GMBH) additionally had initiated legal action (Biogen International GMBH v.